RA Capital Management and Biopharma

Selected healthcare news for the capital firm - RA Capital Management, and the healthcare topic - Biopharma. We have 21 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/10/2022 Daiwa Securities Group Inc. Takes Position in Connect Biopharma Holdings Limited (NASDAQ:CNTB) - Ticker Report Ticker Report Daiwa Securities Group Inc. acquired a new stake in Connect Biopharma Holdings Limited (NASDAQ:CNTB) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 6,069 shares of the company‚Aos stock, valued at approximately $147,000.Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CNTB. RA Capital Management L.P ...
10/24/2021 Connect Biopharma (NASDAQ:CNTB) Shares Gap Down to $17.67 - Ticker Report Ticker Report Connect Biopharma Holdings Limited (NASDAQ:CNTB) gapped down prior to trading on Friday . The stock had previously closed at $17.67, but opened at $16.85. Connect Biopharma shares last traded at $16.85, with a volume of ... investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new position in shares of Connect Biopharma during the 1st quarter worth about $55,337,000. Zimmer Partners LP acquired a ...
9/26/2021 Connect Biopharma (NASDAQ:CNTB) Shares Gap Up to $21.12 - The Cerbat Gem Shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB) gapped up prior to trading on Friday . The stock had previously closed at $21.12, but opened at $21.95. Connect Biopharma shares last traded at $21.95, with a ... institutional investors have recently modified their holdings of the company. RA Capital Management L.P. boosted its holdings in shares of Connect Biopharma by 133.7% during the 2nd quarter. RA Capital Management L.P. now owns 6,991,003 ...
9/22/2021 Connect Biopharma (NASDAQ:CNTB) Shares Gap Down to $23.06 - The Cerbat Gem Shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB) gapped down prior to trading on Monday . The stock had previously closed at $23.06, but opened at $20.03. Connect Biopharma shares last traded at $20.12, with a ... have recently made changes to their positions in the company. RA Capital Management L.P. increased its holdings in shares of Connect Biopharma by 133.7% during the 2nd quarter. RA Capital Management L.P. now owns 6,991,003 ...
9/10/2021 Vor Biopharma Inc. (NYSE:VOR) Receives $48.20 Consensus Price Target from Brokerages Vor Biopharma Inc. (NYSE:VOR) has received a consensus recommendation of ‚AuHold‚Au from the six research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating ... investors have recently bought and sold shares of the stock. RA Capital Management L.P. acquired a new position in shares of Vor Biopharma during the 1st quarter valued at $479,314,000. 5AM Venture Management LLC acquired ...
9/7/2021 Vor Biopharma Inc. (NYSE:VOR) Receives Average Rating of ‚ÄúHold‚Äù from Analysts - Watch List News Vor Biopharma Inc. (NYSE:VOR) has earned an average recommendation of ‚AuHold‚Au from the six brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating and ... hedge funds have recently bought and sold shares of VOR. RA Capital Management L.P. acquired a new stake in shares of Vor Biopharma in the first quarter valued at about $479,314,000. 5AM Venture Management LLC ...
7/15/2021 Vor Biopharma (NYSE:VOR) Sets New 1-Year Low at $17.09 Vor Biopharma Inc. (NYSE:VOR)‚Aos share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $17.09 and last traded at $17.24, with a volume ... have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new position in Vor Biopharma in the 1st quarter valued at about $479,314,000. 5AM Venture Management LLC purchased a ...
7/11/2021 Vor Biopharma (NYSE:VOR) Shares Down 2.7% Vor Biopharma Inc. (NYSE:VOR) fell 2.7% during trading on Friday . The company traded as low as $19.24 and last traded at $19.26. 747 shares traded hands during mid-day trading, a decline of 99 ... hedge funds have recently bought and sold shares of VOR. RA Capital Management L.P. bought a new position in Vor Biopharma in the first quarter valued at about $479,314,000. 5AM Venture Management LLC bought a ...
7/9/2021 Vor Biopharma (NYSE:VOR) Stock Price Down 2.7% American Banking News Vor Biopharma Inc. (NYSE:VOR) shares traded down 2.7% during mid-day trading on Friday . The stock traded as low as $19.24 and last traded at $19.26. 747 shares changed hands during mid-day 99 ... investors have recently made changes to their positions in VOR. RA Capital Management L.P. bought a new stake in Vor Biopharma during the first quarter worth approximately $479,314,000. 5AM Venture Management LLC bought a new ...
7/9/2021 Vor Biopharma (NYSE:VOR) Stock Price Down 2.7% Vor Biopharma Inc. (NYSE:VOR) shares traded down 2.7% during mid-day trading on Friday . The stock traded as low as $19.24 and last traded at $19.26. 747 shares changed hands during mid-day trading ... investors have recently made changes to their positions in VOR. RA Capital Management L.P. bought a new stake in Vor Biopharma during the first quarter worth approximately $479,314,000. 5AM Venture Management LLC bought a new ...
6/30/2021 POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company Globe Newswire ... Biopharma Inc. (‚AuPOINT‚Au), a company accelerating the discovery, development and global access to radiopharmaceuticals, today announced the completion of its business combination with Therapeutics Acquisition Corp., d/b/a Research Alliance Corp. I (Nasdaq: RACA) (‚AuRACA‚Au), a special purpose acquisition company (‚AuSPAC‚Au), sponsored by RA Capital Management. POINT Biopharma Global Inc. (‚AuNew POINT‚Au), the resulting combined company, will commence trading shares of its common stock on ...
6/29/2021 Gilead, Foresite take an unknown pandemic antiviral public in $250M SPAC deal ‚Äì Endpoints News ... RA Capital Management and Frazier Life Sciences.Keep reading Endpoints with a free subscription Unlock this story instantly and join 111,500+ biopharma pros reading Endpoints daily ‚Ai and it's free.SIGN UP LOG IN ...
10/22/2020 Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines -- Creating new category of cellular medicines -- CAMBRIDGE, Mass., October 22, 2020-- Be Biopharma (“Be Bio”), a leader in developing B cells as medicines, founded by Longwood Fund, David Rawlings, MD, and Richard James, PhD, today announced a $52 million Series A financing led by Atlas Venture and RA Capital Management and joined by Alta Partners ...
8/26/2020 Kinnate bags $98M to push next-gen targeted cancer meds into the clinic | FierceBiotech FierceBiotech ... and even then, their tumors often develop resistance to targeted drugs, or the drugs may not work at all. Kinnate Biopharma is looking to change that, and it’s just raised $98 million to push its ... start to pop up.” The series C financing, led by RA Capital Management, will drive a trio of programs toward the clinic and support research programs, too. Kinnate’s backers Foresite Capital, OrbiMed, Nextech Invest and ...
8/24/2020 Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs PR Newswire In an oversubscribed round, top-tier investors provide significant financial resources to accelerate clinical development of potentially best-in-class therapies for inflammatory/autoimmune diseases - SAN DIEGO and TAICANG, SUZHOU, China Connect Biopharma ("Connect"), a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, today announced the completion of a $115 million Series C financing led by new investor RA Capital Management. Additional new ...
7/7/2020 Vor Biopharma Closes $110 Million Series B Financing | Business & Finance | manchestertimes.com Business Wire CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 7, 2020-- Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing ... innovations in oncology,” said Joshua Resnick, MD, Managing Director at RA Capital Management. “We are proud to support the efforts of their impressive team of experienced leaders and drug developers as they work aggressively to ...
6/26/2020 Biotech raises $78M to unleash immune system's natural killers against cancer San Diego’s Artiva Biotherapeutics announced Thursday that it has raised $78 million to develop new ways to direct the immune system against cancer. The Series A financing round was co-led by 5AM Ventures, venBio Partners and RA Capital Management. Enlisting immune cells in the fight against cancer has become a popular goal in the biopharma world. One strategy involves taking a class of immune cells known as T cells ...
5/14/2020 Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire SOUTH SAN FRANCISCO, Calif. , May 14, Sutro Biopharma, Inc. (Nasdaq: STRO ), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a ... Baillie Gifford, BVF Partners L.P., EcoR1 Capital, Eventide Asset Management, RA Capital Management, and Samsara BioCapital, among others. The shares were offered by Sutro pursuant to a registration statement on Form S-3 previously filed ...